Seelos to Test Potential Parkinson’s Treatment Targeting Alpha-synuclein Clumps
Seelos Therapeutics has acquired an exclusive license to further develop a treatment approach called SLS-007 for Parkinson’s disease which is intended to lessen the aggregation of alpha-synuclein protein. The therapeutic strategy was developed by scientists at University of California, Los Angeles, and includes a family of peptide blockers that…